MedTrace Logo

Urine Omics Predicting IO Therapy Responses in mUC Patients

NCT04641936 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2024-04-17

No results posted yet for this study

Summary

The study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving IO-based therapies for metastatic urothelial carcinoma.

Conditions

  • Metastatic Urothelial Carcinoma

Interventions

OTHER

No intervention required

No intervention required

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Yeong Shiau Pu, MD PhD · Department of Urology, National Taiwan University Hospital

Eligibility

Min Age
20 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-17
Primary Completion
2025-10-31
Completion
2027-10-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04641936 on ClinicalTrials.gov